Related Experiment Video
Updated: Jan 11, 2026

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
Published on: September 24, 2021
Temporal Trends and Prognostic Impact of Pacemaker-Associated Heart Failure: Insights from a Nationwide Cohort Study
Young Jun Park1, Sungjoo Lee2,3, Sungjun Hong2
1Division of Cardiology, Department of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea.
Insights
Pacemaker-associated heart failure (PaHF) significantly increases mortality risk after device implantation. This real-world study highlights the persistent and dynamic nature of this risk, emphasizing the need for ongoing cardiac monitoring and tailored pacing strategies.
Area of Science:
- Cardiology
- Medical Devices
- Public Health
Background:
- Pacemaker-associated heart failure (PaHF) is a known complication of chronic ventricular pacing.
- Previous research on PaHF is limited by small sample sizes and insufficient long-term analysis.
- The long-term incidence and prognostic impact of PaHF require further investigation.
Purpose of the Study:
- To evaluate the incidence of PaHF in a large, nationwide cohort.
- To identify clinical predictors associated with PaHF development.
- To assess the mortality risk associated with PaHF following pacemaker implantation.
Main Methods:
- Utilized the Korean National Health Insurance Service database for a nationwide cohort study.
- Included 32,216 patients undergoing de novo pacemaker implantation between 2008 and 2019.
- Analyzed incidence, predictors, and mortality risk of PaHF over a median follow-up of 3.8 years.
Main Results:
- 12.9% of patients developed new-onset PaHF, with a 19.2% overall mortality rate.
- PaHF was independently linked to a 3.11-fold increase in all-cause mortality (aHR: 3.11, 95% CI: 2.93-3.32).
- The incidence and mortality risk of PaHF peaked early but remained elevated, with a late resurgence in mortality.
Conclusions:
- PaHF development is associated with substantial and sustained increased mortality risk post-pacemaker implantation.
- The dynamic and persistent nature of this risk necessitates longitudinal cardiac monitoring.
- Individualized pacing strategies and surveillance are crucial for mitigating adverse long-term outcomes.
Abstract:
Background/Objectives: Pacemaker-associated heart failure (PaHF) is a recognized complication of chronic ventricular pacing, yet its long-term incidence and prognostic impact remain incompletely defined. Previous studies on PaHF have been largely limited by small sample sizes, single-center designs, and insufficient long-term or time-dependent analyses. We aimed to evaluate the incidence, clinical predictors, and mortality risk of PaHF in a nationwide real-world cohort. Methods: Using the Korean National Health Insurance Service database, we identified 32,216 patients who underwent de novo pacemaker implantation between 2008 and 2019 without prior heart failure. Results: During a median follow-up of 3.8 years, 4170 patients (12.9%) developed new-onset PaHF and 6184 (19.2%) died. PaHF was independently associated with increased all-cause mortality (adjusted hazard ratio [HR]: 3.11, 95% confidence interval [CI]: 2.93-3.32, p < 0.001), even after accounting for immortal-time bias and relevant covariates. The incidence of PaHF and its associated mortality risk both peaked within the first six months post implantation and remained persistently elevated throughout follow-up; notably, PaHF-associated mortality showed a late resurgence. Sensitivity and subgroup analyses consistently demonstrated higher mortality among patients with PaHF across a wide range of clinical characteristics. Conclusions: In this large, nationwide cohort, the development of PaHF was associated with a substantial and sustained increase in mortality risk following pacemaker implantation. Given the persistent and dynamic nature of this risk, longitudinal monitoring of cardiac function and individualized pacing strategies may be warranted to mitigate long-term adverse outcomes. Additionally, these findings provide real-world benchmarks to guide future pacing strategies and surveillance efforts.
More Related Videos
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure II: Pathophysiology
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure III: Clinical Manifestations
Pulse rhythm
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...

